Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptose Biosciences, Inc. - Common Shares (TSX:APS)

2.200 -0.070 (-3.08%)
Streaming Delayed Price Updated: 1:33 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,903
Open 2.270
Bid (Size) 2.180 (5)
Ask (Size) 2.310 (114)
Prev. Close 2.270
Today's Range 2.190 - 2.270
52wk Range 0.1550 - 5.800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
Aptose Biosciences minority shareholders to receive C$2.41 in cash per share in a “go private” transaction 
From Aptose Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
+566.7%
+566.7%
1 Month
+7.3%
+7.3%
3 Month
+35.0%
+35.0%
6 Month
+22.9%
+22.9%
1 Year
+700.0%
+700.0%

More News

Read More
News headline image
Aptose Reports Third Quarter 2025 Results
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Reports Second Quarter 2025 Results
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Upgraded to Trade on OTCQB Market
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Announces Deferral of Interest Payment
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Provides Corporate Updates
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Announces Results from Annual and Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Reports First Quarter 2025 Results
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Announces Auditor Not Standing for Re-Appointment
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
From Aptose Biosciences, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Aptose Biosciences, Inc. - Common Shares publicly traded?
Yes, Aptose Biosciences, Inc. - Common Shares is publicly traded.
What exchange does Aptose Biosciences, Inc. - Common Shares trade on?
Aptose Biosciences, Inc. - Common Shares trades on the Toronto Stock Exchange
What is the ticker symbol for Aptose Biosciences, Inc. - Common Shares?
The ticker symbol for Aptose Biosciences, Inc. - Common Shares is APS on the Toronto Stock Exchange
What is the current price of Aptose Biosciences, Inc. - Common Shares?
The current price of Aptose Biosciences, Inc. - Common Shares is 2.200
When was Aptose Biosciences, Inc. - Common Shares last traded?
The last trade of Aptose Biosciences, Inc. - Common Shares was at 12/16/25 01:33 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.